Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.74 |
| ▸ | NAT1 | P18440 | 1/20 | 0.66 |
| ▸ | TTR | P02766 | 3/20 | 0.61 |
| ▸ | IGF1R | P08069 | 1/20 | 0.61 |
| ▸ | PIM1 | P11309 | 2/20 | 0.61 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.61 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.58 |
| ▸ | GSK3B | P49841 | 2/20 | 0.57 |
| ▸ | TDP2 | O95551 | 1/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
| ▸ | CASP9 | P55211 | 1/20 | 0.56 |
| ▸ | CASP6 | P55212 | 1/20 | 0.56 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6929414 | 1.00 | TDP1 (0.74) | TDP1NAT1TTRIGF1RPIM1 | |
| SCHEMBL18103098 | 0.85 | NAT1 (0.68) | TDP1NAT1PIM1GSK3B | |
| SCHEMBL11730105 | 0.85 | NAT1 (0.68) | TDP1NAT1PIM1GSK3B | |
| SCHEMBL14860997 | 0.85 | TDP1 (1.00) | TDP1MEN1KMT2ATDP2ALDH1A1 | |
| SCHEMBL14860994 | 0.85 | TDP1 (1.00) | TDP1MEN1KMT2ATDP2ALDH1A1 | |
| SCHEMBL6419026 | 0.85 | TDP1 (0.59) | TDP1NAT1TTRIGF1RPIM1 | |
| SCHEMBL6419028 | 0.85 | TDP1 (0.59) | TDP1NAT1TTRIGF1RPIM1 | |
| SCHEMBL14860995 | 0.85 | TDP1 (1.00) | TDP1MEN1KMT2ATDP2ALDH1A1 | |
| SCHEMBL1248983 | 0.85 | KMT2A (0.59) | TDP1NAT1TTRIGF1RPIM1 | |
| SCHEMBL1248985 | 0.85 | KMT2A (0.59) | TDP1NAT1TTRIGF1RPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
| US-6518268-B1 | Telomerase inhibitors and methods of their use | GERON CORPORATION | 2003-02-11 | — | — | US | disclosed |
| WO-2001002377-A9 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORP (US) | 2001-10-11 | — | — | WO | disclosed |
| EP-1109796-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | Geron Corporation (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001002377-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | TDP1 4829/4885NAT1 4542/4885TTR 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.